Literature DB >> 19088264

Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.

Catherine Weber1, Gilbert B Zulian.   

Abstract

In the case of malignant intestinal obstruction, surgery often carries important mortality and morbidity risks, and feasibility is neither realistic nor reasonable. A total of 4 clinical cases of intestinal obstruction caused by advanced gastrointestinal cancers in their terminal phase are described. The association of analgesics, corticosteroids, antiemetics, and octreotide was effective to relieve symptoms of intestinal obstruction for the remaining lifetime. The insertion of a nasogastric tube was avoided in 3 of 4 cases. Death occurred 51, 56, and 64 days after clinical and radiological diagnosis of irreversible intestinal obstruction. This combination of drugs appears very powerful and well tolerated. The relatively long survival that was observed should encourage future studies of longer half-life somatostatin analogues with no need of continuous infusion or multiple daily injections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088264     DOI: 10.1177/1049909108327967

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  4 in total

Review 1.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

2.  Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.

Authors:  Michael Hwang; Rosene Pirrello; Minya Pu; Karen Messer; Eric Roeland
Journal:  Support Care Cancer       Date:  2013-06-04       Impact factor: 3.603

3.  Malignant bowel obstruction: A retrospective clinical analysis.

Authors:  Jia-Hong Chen; Tzu-Chuan Huang; Ping-Ying Chang; Ming-Shen Dai; Ching-Liang Ho; Yeu-Chin Chen; Tsu-Yi Chao; Woei-Yau Kao
Journal:  Mol Clin Oncol       Date:  2013-11-19

4.  MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.

Authors:  Ainhoa Madariaga; Jenny Lau; Arunangshu Ghoshal; Tomasz Dzierżanowski; Philip Larkin; Jacek Sobocki; Andrew Dickman; Kate Furness; Rouhi Fazelzad; Gregory B Crawford; Stephanie Lheureux
Journal:  Support Care Cancer       Date:  2022-03-10       Impact factor: 3.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.